Industry News

Pfizer Inc. executive who also is on the Preston school board, said he expects to fill the position for six to nine months as SeCTer seeks a permanent replacement."/>
Preston Redevelopment Agency chairman takes helm at SeCTer [The Day, New London, Conn.]
Hikma Pharmaceuticals Plc. posted a 24 per cent increase in its earnings during the first half of the year, bringing its total revenue to $882 million, according to a company statement. Hikma, a multinational pharmaceutical group, has recently reported its interim results for the six months ending June 30.. In addition to completing the West-Ward Columbus acquisition and making considerable progress in integrating its business, the group has also made strides in..."/>
Hikma delivers 'solid first half performance in transitional year' [Jordan Times, Amman]
Mallinckrodt has entered into an agreement to sell its nuclear imaging business to IBA Molecular for $690 million, the company said Wednesday. The Hazelwood-based drug manufacturer said it is moving away from nuclear imaging to continue its focus on high-growth specialty pharmaceuticals. The deal affects 800 employees and two manufacturing facilities, including one in Maryland Heights."/>
Mallinckrodt to sell nuclear imaging business [St. Louis Post-Dispatch]
Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today announced that the Company has converted a senior secured three year convertible debenture of $12.5 million of principal and $8.25 million of interest to 6,102,941 shares of its common stock. The conversion was effected in accordance with the previously announced purchase agreement entered into between Cesca Therapeutics and Boyalife USA, dated..."/>
Cesca Therapeutics Announces Conversion of $12.5 Million in Senior Secured Debt to Equity
Prima BioMed Ltd announces the granting of patent number 2142210 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the European Patent Office. The patent relates to Prima's IMP731 antibody. The granted claims provide protection for specific sequences of anti-LAG-3 antibodies and their use in depleting LAG-3+ T cells by complement dependent..."/>
European Patent Grants for IMP731 Antibody
Comcast Corp.' s NBCUniversal division..."/>
M and A Navigator: Deal pipeline –24 August
ProMetic Life Sciences Inc. has agreed to acquire Canadian biotechnology company Telesta Therapeutics, Inc, the company said. Under the terms of the Agreement, ProMetic will acquire all of the share capital of Telesta at a share price of CDN 0.14 payable in ProMetic common shares. The number of common shares to be issued by ProMetic will be based on the volume-weighted average closing price of ProMetic's common shares for the..."/>
ProMetic Agrees to Acquire Canadian Biotechnology Firm Telesta Therapeutics
Mesoblast Limited today reported its consolidated financial results and operational highlights for the three months ended 30 June 2016 and year ended 30 June 2016. Mesoblast ended FY16 with cash reserves of US $80.9 million. The Company reduced its annual operating and investing cash outflows by 15% to US $89.7 million for FY16 in comparison with the prior financial year."/>
Mesoblast Reports Financial Results and Operational Highlights for the Three Months and for the Year Ended 30 June 2016
Amgen today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for the New Drug Application for Parsabiv™ for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. Amgen is reviewing the Complete Response Letter, and we anticipate a post-action meeting with the FDA later this year to discuss the Complete Response."/>
Amgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)
Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes, today announced an amendment of its Cooperative Research and Development Agreement with the National Cancer Institute to extend the CRADA for an additional five-year term until 2021. Under the extended CRADA, the Company will continue working with Steven A. Rosenberg, M.D., Ph.D., chief of NCI's Surgery Branch, to develop..."/>
Lion Biotechnologies Announces 5-Year Extension of National Cancer Institute CRADA for Development of Novel TIL Immuno-Oncology Therapies
Teva Pharmaceutical Industries Ltd. today confirmed the Patent Trial and Appeal Board decisions from an Inter Partes Review to invalidate all claims of the‘ 250 and‘ 413 patents for 40 mg COPAXONE ®. Teva plans to appeal to the United States Court of Appeals for the Federal Circuit. “We remain confident in the strength of our intellectual property surrounding COPAXONE ® 40 mg."/>
Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mg
Pfizer Inc. has agreed to acquire the development and commercialization rights to Europe-based pharmaceutical company AstraZeneca's late-stage small molecule anti-infectives business, primarily outside the United States, for USD 725 m, the company said. Under the terms of the agreement, Pfizer will make an upfront payment of USD 550 m to AstraZeneca upon the close of the transaction and a deferred payment of USD 175 m in..."/>
Pfizer to Acquire AstraZeneca’s Small Molecule Anti-Infective Business for USD 725m
Mallinckrodt plc has entered into a definitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular for approximatelyUSD 690 m, the company said on Wednesday. This total is before tax impacts, including up-front and contingent consideration and the assumption of long-term obligations. IBA Molecular is manufacturer and distributor of radiopharmaceutical products."/>
Mallinckrodt Enters Agreement to Sell Nuclear Imaging Business in USD 690m Deal
Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Robert W. Baird Global Healthcare Conference on Wednesday, September 7, 2016, at 3:10 p.m. EDT in New York City. A live audio webcast for this event will be available in the..."/>
Glaukos Announces Participation in Baird Healthcare Conference
Hill-Rom Holdings, Inc., invites you to listen to a management presentation at the Morgan Stanley Global Healthcare Conference on Monday, Sept. 12, 2016, at 9:55 a.m. EDT. The live audio webcast of the presentation can be accessed at cfm. A recorded replay will be available one hour after conclusion of the live event through Oct. 12, 2016.."/>
Hill-Rom to Participate in the Morgan Stanley Global Healthcare Conference
Titan Medical Inc. today announced that it extended the rights granted to Longtai Medical Inc. to negotiate an exclusive marketing, sales and distribution agreement for Titan's SPORT™ Surgical System in the Asia Pacific Region. The parties have agreed to modify their previous three-month extension to monthly progress reviews. The granting of exclusive rights to negotiate a distribution agreement continues to be part of the Letter Agreement with..."/>
Titan Medical Extends Negotiating Period With Longtai Medical Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary643 Articles
Information Technology602 Articles
Financials515 Articles
Health Care366 Articles
Industrials357 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at